Platelet Function Testing

Patients who do not respond to their antiplatelet medication may be significantly at a greater risk of ischemic events and death. The VerifyNow System provides a state of the art platform for the assessment of all major antiplatelet therapies in minutes!

Expand All - Collapse All

VerifyNow System

VerifyNow Analyser Sophisticated Science, Easy-To-Operate Package Utilizing an automated analyzer with single-use, disposable assays, the VerifyNow® System offers numerous advantages over the other methods of measuring platelet response. •Simple - Whole blood, closed-tube samples require no preparation for analysis. •Rapid - Platelet response is reported in five minutes or less. •Reliable - Results are consistent across a wide range of patients and settings. •Accurate - Measurements correlate with optical aggregometry. •Convenient - Assays can be used at the patient point-of-care and VerifyNow Aspirin is CLIA waived for use in physician offices. VerifyNow results are comparable to platelet aggregometry but are far less time- and labor-intensive. View Brochure

P2Y12 Assay

VerifyNow® P2Y12 Thienopyridines such as Plavix® (clopidogrel) and Effient® (prasugrel) block the P2Y12 ADP binding site on the platelet. The VerifyNow P2Y12 Test uses an ADP agonist to induce platelet activation and ascertain the level of platelet reactivity impaired by these medications. It also incorporates a second channel containing thrombin receptor agonists to approximate baseline reactivity so that there is no need to discontinue antiplatelet medication. Studies show that up to 30% of patients taking Plavix have low levels of platelet inhibition (reactivity)1,2 and do not receive the expected antiplatelet effect which may increase the risk of ischemic events or unnecessarily delayed from surgery. The quantitative test is a simple measurement to help assess the patient’s level of response to their therapy. VerifyNow P2Y12 Test also Measures Response to Prasugrel With the recent FDA approval of the new P2Y12 inhibitor, prasugrel (Effient®), Accumetrics, Inc. announces that its VerifyNow P2Y12 Test is not only able to assess response to Plavix, but also the newly approved Effient. In obtaining a result from the VerifyNow System, physicians are provided objective information to determine the response of an individual patient to their antiplatelet therapy, regardless of the P2Y12 inhibitor that is prescribed. View Brochure

Aspirin Assay

VerifyNow Aspirin Assay Aspirin binds to the COX-1 enzyme to prevent the conversion of arachidonic acid to thromboxane A22, which result in platelet activation. The VerifyNow® Aspirin Assay utilizes arachidonic acid as the agonist to measure platelet function specifically along this pathway. Research shows that patients response to aspirin varies1,2, and up to a quarter of patients are not responding adequately to its antiplatelet effects.3 These patients are 2-3 times more likely to have a major heart attack or stroke.3 The VerifyNow Aspirin Assay provides a simple measurement to determine whether or not a patient is responding to their aspirin therapy. View Brochure

VerifyNow IIb/IIIa Assay

VerifyNow IIb/IIIa Assay Glycoprotein (GP) IIb/IIIa inhibitors such as ReoPro® and Integrilin® are fast acting and powerful inhibitors of platelet aggregation that prevent the binding of platelets to fibrinogen. The VerifyNow® IIb/IIIa assay utilizes a thrombin receptor activating peptide as an agonist to maximally stimulate the platelet and determine the level of platelet function. Research shows that patients’ response to weight-based dosing varies, and the assay provides clinicians with an accurate assessment of platelet blockade within two minutes from the time of sample collection. View Brochure VerifyNow Cleaning Device Cleaning device to keep VerifyNow system in good condition. Must be used once every month. View Brochure